法匹拉韦治疗新冠肺炎临床研究进展

新型冠状病毒肺炎(COVID-19)疫情在全球大流行,临床上迫切需要特异性抗病毒治疗药物。对已批准上市或正在临床开发的药物开展重定位研究是针对突发疫情快速寻找潜在治疗药物最为快速和高效的策略。法匹拉韦是一种广谱抗RNA病毒药物,在日本和中国已批准上市用于治疗流感,其作为抗新型冠状病毒感染的潜在药物,全球多个国家正在开展相关临床试验,初步的结果令人鼓舞。本文主要综述在中国、日本、俄罗斯和印度等国家开展的法匹拉韦单用或联合其他药物治疗COVID-19的临床试验,考察用药剂量、试验设计、药物有效性和安全性等。研究结果显示,法匹拉韦在针对COVID-19轻症和中症患者的治疗中,能够有效提高患者病毒RNA清除率或改善临床恢复率,且表现出良好的安全性。本文对法匹拉韦治疗COVID-19临床研究进展进行总结,为其在抗COVID-19治疗中的应用提供参考。

Clinical research progress in treatment of coronavirus disease 2019(COVID-19) with favipiravir

The coronavirus disease 2019(COVID-19)pandemic has led to the urgent need to develop therapeutic drugs to respond to disease progression and treatment of patients.Drug repurposing is one of the potential ways to rapidly find treatments for emerging viral infection.Favipiravir is a novel broad-spectrum antiviral drug that has been approved for new and re-emerging pandemic influenza.As a potential drug against severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,favipiravir is currently under clinical trials in several countries and has shown promising results in clinical studies.This paper reviews the clinical studies on the treatment of COVID-19 with favipiravir or combination with other drugs by focusing on the data about dose,trial design,efficacy and safety in China,Japan,Russia and India.Favipiravir with proven safety profiles has proved to be effective in improving viral RNA clearance or clinical recovery in patients with mild and moderate symptoms.This review will help gain insights into the evidence based role of favipiravir in antiviral therapy of COVID-19.